Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.51 |
| ▸ | SORD | Q00796 | 2/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | OGA | O60502 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29519276 | 1.00 | TRPV1 (0.51) | TRPV1SORDCXCR4HRH3OGA | |
| SCHEMBL2087838 | 0.98 | CXCR4 (0.51) | TRPV1SORDCXCR4HRH3OGA | |
| SCHEMBL1088796 | 0.98 | CXCR4 (0.51) | TRPV1SORDCXCR4HRH3OGA | |
| SCHEMBL1427479 | 0.96 | TRPV1 (0.51) | TRPV1SORDCXCR4HRH3OGA | |
| SCHEMBL28219653 | 0.85 | TRPV1 (0.49) | TRPV1SORDHRH3OGAHRH4 | |
| SCHEMBL2190955 | 0.83 | HRH4 (0.65) | TRPV1SORDHRH3CYP1A2HRH4 | |
| SCHEMBL29997962 | 0.83 | HRH4 (0.65) | TRPV1SORDHRH3CYP1A2HRH4 | |
| SCHEMBL1110658 | 0.83 | PIK3CA (0.50) | TRPV1SORDOGACYP1A2 | |
| SCHEMBL11823109 | 0.83 | TRPV1 (0.48) | TRPV1SORDHRH3OGAHRH4 | |
| SCHEMBL5585319 | 0.83 | HRH3 (0.65) | TRPV1HRH3CYP1A2HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288559-A1 | PREP BINDING LIGANDS | POLKU THERAPEUTICS OY (FI) | 2025-09-18 | — | — | US | disclosed |
| WO-2025128893-A1 | FUSED QUINONE COMPOUNDS | ACUREX BIOSCIENCES CORPORATION (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4514781-A1 | PREP BINDING LIGANDS | Polku Therapeutics OY (FI) | 2025-03-05 | — | — | EP | disclosed |
| EP-4423090-A2 | ANTAGONISTS OF GPR39 PROTEIN | Vasocardea, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023229380-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2023-11-30 | — | — | WO | disclosed |
| WO-2023209191-A1 | PREP BINDING LIGANDS | UNIVERSITY OF HELSINKI (FI) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023209191-A1 | PREP BINDING LIGANDS | UNIVERSITY OF HELSINKI (FI) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023076219-A2 | ANTAGONISTS OF GPR39 PROTEIN | VASOCARDEA, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076219-A2 | ANTAGONISTS OF GPR39 PROTEIN | VASOCARDEA, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| CN-113307791-B | Pyrimidylpiperazine urea TRPV1 antagonistic/MOR agonistic double-target compound and preparation method and application thereof | 河南大学 | 2022-04-12 | — | — | CN | disclosed |
| US-9505767-B2 | Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors | GENENTECH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| EP-3041474-A1 | ANTIPROLIFERATIVE COMPOUNDS | Genentech, Inc. (US) | 2016-07-13 | — | — | EP | disclosed |
| WO-2016087343-A1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | WO | disclosed |
| WO-2015035062-A1 | ANTIPROLIFERATIVE COMPOUNDS | GENENTECH, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20150065522-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2015-03-05 | — | — | US | disclosed |
| US-8962641-B2 | Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-24 | — | — | US | disclosed |
| US-20140315882-A1 | PYRIMIDINE-SUBSTITUTED PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-23 | — | — | US | disclosed |
| WO-2009029617-A1 | DIARYLAMINE-SUBSTITUTED QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| EP-2008210-A1 | MODULATION OF PHOSPHORYL TRANSFERASE ACTIVITY OF GLUTAMINE SYNTHETASE | CSIR (ZA) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007105023-A1 | MODULATION OF PHOSPHORYL TRANSFERASE ACTIVITY OF GLUTAMINE SYNTHETASE | CSIR (ZA) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065522-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM5A, KDM5B, KDM5C | TRPV1 3792/4885SORD 3461/4885CXCR4 1940/4885 |
| US-20140315882-A1 | PYRIMIDINE-SUBSTITUTED PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TYMP, APRT, TYMS | TRPV1 1187/4885SORD 1515/4885CXCR4 1400/4885 |
| US-20250288559-A1 | PREP BINDING LIGANDS | PREP, ERAP2, CTSA | TRPV1 1084/4885SORD 3310/4885CXCR4 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.